Evidence map›Paper›PMID 32365495›Full record

ReviewPharmaceutics2020

Polymer-Drug Conjugate, a Potential Therapeutic to Combat Breast and Lung Cancer.

Sibusiso Alven, Xhamla Nqoro, Buhle Buyana, Blessing A Aderibigbe

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pharmaceutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Antibody-Biopolymer Conjugates in Oncology: A Review.Molecules (Basel, Switzerland) · 2023
    Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Sibusiso AlvenDepartment of Chemistry, University of Fort Hare, Alice Eastern Cape 5700, South Africa.
Xhamla NqoroDepartment of Chemistry, University of Fort Hare, Alice Eastern Cape 5700, South Africa.ORCID 0000-0001-7100-4007
Buhle BuyanaDepartment of Chemistry, University of Fort Hare, Alice Eastern Cape 5700, South Africa.
Blessing A AderibigbeDepartment of Chemistry, University of Fort Hare, Alice Eastern Cape 5700, South Africa.

Funding

South African Medical Research Council SAMRC
6 · The paper itself

Abstract

Cancer is a chronic disease that is responsible for the high death rate, globally. The administration of anticancer drugs is one crucial approach that is employed for the treatment of cancer, although its therapeutic status is not presently satisfactory. The anticancer drugs are limited pharmacologically, resulting from the serious side effects, which could be life-threatening. Polymer drug conjugates, nano-based drug delivery systems can be utilized to protect normal body tissues from the adverse side effects of anticancer drugs and also to overcome drug resistance. They transport therapeutic agents to the target cell/tissue. This review article is based on the therapeutic outcomes of polymer-drug conjugates against breast and lung cancer.

Indexed as

breast cancerchemotherapylung cancerpolymer-based carrierspolymer-drug conjugates

Identifiers

PMID32365495
PMCPMC7284459

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.